Your browser is no longer supported. Please, upgrade your browser.
Settings
MRK Merck & Co., Inc. daily Stock Chart
MRK [NYSE]
Merck & Co., Inc.
IndexDJIA S&P500 P/E23.95 EPS (ttm)3.72 Insider Own0.08% Shs Outstand2.56B Perf Week1.97%
Market Cap227.92B Forward P/E15.91 EPS next Y5.60 Insider Trans-10.72% Shs Float2.54B Perf Month6.59%
Income9.67B PEG2.41 EPS next Q1.16 Inst Own77.70% Short Float0.86% Perf Quarter7.45%
Sales45.97B P/S4.96 EPS this Y33.00% Inst Trans-1.02% Short Ratio2.60 Perf Half Y6.44%
Book/sh10.49 P/B8.49 EPS next Y8.46% ROA11.20% Target Price97.56 Perf Year15.09%
Cash/sh3.13 P/C28.43 EPS next 5Y9.95% ROE34.30% 52W Range70.89 - 89.24 Perf YTD16.61%
Dividend2.44 P/FCF66.92 EPS past 5Y10.60% ROI11.70% 52W High-0.16% Beta0.52
Dividend %2.74% Quick Ratio1.00 Sales past 5Y-0.80% Gross Margin70.50% 52W Low25.69% ATR1.13
Employees69000 Current Ratio1.30 Sales Q/Q14.90% Oper. Margin25.60% RSI (14)69.37 Volatility1.06% 1.24%
OptionableYes Debt/Eq0.97 EPS Q/Q1.50% Profit Margin20.30% Rel Volume0.96 Prev Close88.72
ShortableYes LT Debt/Eq0.84 EarningsOct 29 BMO Payout61.00% Avg Volume8.38M Price89.10
Recom1.80 SMA203.37% SMA505.10% SMA2007.71% Volume8,065,875 Change0.43%
Oct-17-19Resumed BofA/Merrill Neutral $90
Aug-16-19Initiated SVB Leerink Outperform
Jul-03-19Initiated Mizuho Buy $97
May-28-19Initiated Goldman Neutral
May-13-19Upgrade Atlantic Equities Neutral → Overweight
Oct-16-18Reiterated Citigroup Buy $70 → $79
Oct-09-18Resumed Guggenheim Buy
Apr-23-18Upgrade Goldman Neutral → Buy
Apr-17-18Upgrade Morgan Stanley Equal-Weight → Overweight
Apr-05-18Upgrade Barclays Equal Weight → Overweight $62 → $64
Mar-12-18Upgrade Leerink Partners Mkt Perform → Outperform
Feb-14-18Reiterated Leerink Partners Mkt Perform $67 → $66
Feb-07-18Reiterated Morgan Stanley Equal-Weight $60 → $63
Jan-16-18Upgrade SunTrust Hold → Buy
Nov-28-17Resumed BofA/Merrill Buy $64
Nov-24-17Reiterated Deutsche Bank Hold $62 → $59
Oct-31-17Upgrade Jefferies Underperform → Hold
Oct-30-17Downgrade SunTrust Buy → Hold
Oct-30-17Downgrade Morgan Stanley Overweight → Equal-Weight
Oct-30-17Downgrade Barclays Overweight → Equal Weight $72 → $62
Dec-10-19 04:31PM  Investors shift attention to next generation of CAR-T, new sickle cell treatments at major hematology meeting MarketWatch
04:16PM  Why Biotech ETFs are Surging to New Highs Zacks
03:11PM  Heres the one Dow stock to buy now if you believe that what goes down must come up MarketWatch
10:10AM  Biotech ETFs Hit New Highs on Deal Activities Zacks
09:42AM  Merck to Buy ArQule for $2.7B to Boost Cancer Portfolio Zacks
08:27AM  Pharma M&As Continue, Merck, Sanofi to Buy Cancer Drug Firms Zacks
07:14AM  Drug manufacturers have spent a record $342 billion on M&A in 2019 MarketWatch
Dec-09-19 05:23PM  The Dow Fell 105 Points Because Trumps China Tariffs Can Kick In Next Week Barrons.com
04:45PM  U.S. stock market snaps 3-day win streak as China tariff deadline comes in focus MarketWatch
04:44PM  Sanofis New CEO Is Aiming for a Narrower Focus in Drug Development Barrons.com
11:51AM  Merck to buy Massachusetts cancer drug developer for $2.7 billion American City Business Journals
11:38AM  US STOCKS-Wall Street treads water with tariff deadline in focus Reuters
11:04AM  Heres the hard-money call for why the boom in the economy and stock market will continue MarketWatch
10:49AM  US STOCKS-S&P 500, Nasdaq edge higher; tariff deadline in focus Reuters
10:44AM  Drug Giants Pay Hefty Premiums as Cancer-Drug Race Heats Up Bloomberg
10:16AM  Week Begins with Biotech Mergers Zacks
10:06AM  Merger Monday, Biotech Edition: MRK, SNY, ARQL, THOR & More Zacks
10:03AM  World's largest biotech company to move up to BioMed's big South City project American City Business Journals
09:59AM  Merck drops $2.7B on 26-year-old Burlington biotech American City Business Journals
09:42AM  Merck and Sanofi Are Both Acquiring Cancer-Drug Developers Barrons.com
09:22AM  Bristol-Myers' (BMY) Lymphoma Drug Meets Goals in Key Study Zacks
09:02AM  Amgen Gets FDA Approval for J&J/Merck's Remicade Biosimilar Zacks
08:42AM  No News Is Bad News for the Dow on Monday Morning Barrons.com
07:27AM  Three Things You Should Check Before Buying Merck & Co., Inc. (NYSE:MRK) For Its Dividend Simply Wall St.
06:56AM  Merck to acquire ArQule for $20 per share in cash or about $2.7 billion MarketWatch
06:45AM  Merck to Acquire ArQule, Advancing Leadership in Oncology Business Wire
04:47AM  Merck & Co. Acquires Cancer Drug Specialist ArQule For $2.7 Billion TheStreet.com
03:45AM  Stocks - Canopy Growth, ArQule Rise in Premarket; Microsoft Edges Lower Investing.com
Dec-06-19 06:10PM  4 Health Care Stocks Gurus Broadly Own GuruFocus.com
09:27AM  Pharma Stock Roundup: FDA Updates for RHHBY, AZN, MRK, No Asbestos in Talc Says JNJ Zacks
09:22AM  AstraZeneca's Lynparza Gets China Nod in First-Line Setting Zacks
Dec-05-19 09:58AM  Bristol-Myers' Orencia Gets Breakthrough Therapy Tag for GvHD Zacks
09:07AM  J&J Stock Witnesses Volatility in '19: What to Expect in 2020 Zacks
06:45AM  LYNPARZA® (olaparib) Approved in China as a First-Line Maintenance Therapy in BRCA-Mutated (BRCAm) Advanced Ovarian Cancer Business Wire
Dec-04-19 05:52PM  Bayer and Teva Double Down on Worst M&A Deals of Decade GuruFocus.com
10:08AM  Bristol-Myers' Reblozyl to be Reviewed by FDA Committee Zacks
10:02AM  Biotech Stock Roundup: Pipeline Updates From BIIB, AXSM, CARA, Collaborations & More Zacks
09:22AM  Roche's Tecentriq-Chemo Combo Gets FDA Nod in First-Line NSCLC Zacks
03:55AM  Pfizer/Astellas Xtandi Gets Nod in China for Prostate Cancer (Revised) Zacks
Dec-03-19 05:03PM  Merck Cyberattacks $1.3 Billion Question: Was It an Act of War? Bloomberg
02:41PM  Merck Cyberattack Raises $1.3 Billion Legal Question Bloomberg
10:45AM  Seattle Genetics, Astellas Tie Up With Merck for Cancer Study Zacks
09:24AM  Merck's Keytruda Gets FDA's Priority Tag in Bladder Cancer Zacks
08:17AM  Large-Cap Pharmaceuticals Industry Prospects Bright for 2020 Zacks
07:59AM  The Daily Biotech Pulse: Astellas To Buy Audentes For $3B, Applied Genetics Chief Medical Officer Quits, Axsome Aces Midstage Trial Benzinga
Dec-02-19 08:57AM  Merck Stock Gains as FDA Accelerates Review of New Use for Blockbuster Cancer Drug Barrons.com
08:30AM  AstraZeneca's (AZN) Imfinzi Gets FDA Priority Tag for SCLC Zacks
06:55AM  Merck to Present at the Evercore ISI HealthCONx Conference 2019 Business Wire
06:45AM  FDA Grants Priority Review to Mercks Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) in Certain Patients with High-Risk, Non-Muscle Invasive Bladder Cancer (NMIBC) Business Wire
Nov-30-19 12:03PM  Heres the real difference between women and men when it comes to stock-market investing MarketWatch
Nov-29-19 11:21AM  The Zacks Analyst Blog Highlights: Merck, Lilly, Charter, Alibaba and Charles Schwab Zacks
Nov-28-19 09:31AM  Why Is Merck (MRK) Up 1.6% Since Last Earnings Report? Zacks
08:44AM  Here's Why Merck's (MRK) Shares Are Up This Year Zacks
07:09AM  Esperion's Promising Drugs Under Review, Funds a Concern Zacks
Nov-27-19 03:53PM  Top Research Reports for Merck, Eli Lilly & Charter Communications Zacks
10:12AM  Merck's Keytruda Gets Nod in China for Difficult Lung Cancer Zacks
07:59AM  [video]Merck Wins Drug Approval and Part of a Court Case; Here's How to Trade the Stock TheStreet.com
07:26AM  The Daily Biotech Pulse: Tonix Says No Surprises In FDA Meeting Minutes, Aravive Offering, FDA Nod For Qiagen Benzinga
07:10AM  Pfizer/Astellas Xtandi Gets Nod in China for Prostate Cancer Zacks
Nov-26-19 05:05PM  US Indexes Close Higher Tuesday, Best Buy Rises 10% GuruFocus.com
03:52PM  Merck, Walt Disney share gains lead Dow's nearly 75-point jump MarketWatch
06:45AM  Mercks KEYTRUDA® (pembrolizumab) Now Approved in China for First-Line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) in Combination with Chemotherapy Business Wire
Nov-25-19 09:45AM  Intel, Merck share gains lead Dow's 100-point jump MarketWatch
09:01AM  Hedge Funds Are Optimistic About Merck & Co., Inc. (MRK) Insider Monkey
06:45AM  New Survey of Young Adults Uncovers Low Levels of Accurate Knowledge About HIV Transmission Coupled with High-Risk Sexual Behaviors PR Newswire
Nov-23-19 03:41PM  Pfizer Is the Dows Worst Stock. A New Strategy Makes It Worth Another Look. Barrons.com
Nov-22-19 04:31PM  Dow Jones Today: Trade Progress Pushes Stocks, Healthcare Helps Dow InvestorPlace
11:31AM  Pharma Stock Roundup: FDA Nod to NVS' & AZN's Drugs, BMY-CELG Merger Closes Zacks
09:41AM  NewsBreak: Trump Looks to Let Florida, Others Import Prescription Drugs Investing.com
08:45AM  Merck (MRK) is an Incredible Growth Stock: 3 Reasons Why Zacks
Nov-21-19 05:58PM  Bristol-Myers' Melanoma Study Misses Goal, Closes Celgene Deal Zacks
10:17AM  Dow drops 75 points on losses for shares of Travelers, Walgreens Boots MarketWatch
10:00AM  Merck's Keytruda Wins EU Nod for First-Line Head/Neck Cancer Zacks
07:00AM  Market Morning: GM Sues Fiat, Pharma Fights for Pricing Privacy, More Opioid Lawsuits, Trade Deal Troubles Market Exclusive
Nov-20-19 11:01AM  Your three-stock survival kit for 2020 packed by Nuveens top stock-market strategist MarketWatch
08:41AM  Medicines Company Up on Rumors of Potential Buyout by Novartis Zacks
06:45AM  European Commission Approves Two New Regimens of Mercks KEYTRUDA® (pembrolizumab) as First-Line Treatment for Metastatic or Unresectable Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) Business Wire
06:30AM  Keytruda researcher launches cancer-focused Werewolf Therapeutics with $56M American City Business Journals
Nov-19-19 12:59PM  Merck raises quarterly dividend, to yield more than peers and the S&P 500 MarketWatch
12:43PM  Merck Announces First-Quarter 2020 Dividend Business Wire
10:33AM  Drug Legislation Likely to Dry Up Biotech Funding GuruFocus.com
10:32AM  Merck's Heart Failure Candidate Meets Goal in Phase III Study Zacks
09:23AM  Novo Nordisk Inks Deal With Dicerna to Develop RNAi Therapies Zacks
Nov-18-19 04:57PM  Gluware teams with Juniper to diagnose complex wireless networks American City Business Journals
10:27AM  Medicines Company Posts Full Inclisiran Data From ASCVD Study Zacks
10:24AM  Beyond Meat Is Shaking Up the Meat Industry. Animal-Health Stocks Could Take a Hit, Too. Barrons.com
09:18AM  Bristol-Myers Gets FTC Clearance for Celgene Acquisition Zacks
07:46AM  Here's Why AstraZeneca's (AZN) Shares Are Up Year to Date Zacks
07:19AM  How to Generate Retirement Income With a Total Return Strategy Barrons.com
07:12AM  5 Blue-Chip Stocks to Buy as Dow Breezes Past 28,000 Zacks
06:30AM  Merck and Bayers Investigational Drug Vericiguat Meets Primary Endpoint in Phase 3 Study of Patients with Worsening Chronic Heart Failure Business Wire
12:18AM  Thiel Marks Palantirs Asia Push with $150 Million Japan Venture Bloomberg
Nov-17-19 07:07AM  Hedge Funds Open Kimono: 5 Best Healthcare Stocks To Buy Insider Monkey
Nov-15-19 09:23AM  AstraZeneca/Merck's Selumetinib NDA Gets FDA Priority Status Zacks
07:12AM  Pharma Stock Roundup: MRK, GSK, ABBV, LLY's Pipeline & Regulatory Updates Zacks
06:45AM  BRAVECTO® PLUS (fluralaner and moxidectin topical solution) for Cats Receives Approval from US Food and Drug Administration Business Wire
06:41AM  4 Big Drugmakers to Bet on After a Great Earnings Season Zacks
05:33AM  Merck KGaA CFO on M&A Hiatus, Third-Quarter Earnings Bloomberg
Nov-14-19 05:26PM  Livongo Bounces Back After Revenue Guidance Boost GuruFocus.com
11:44AM  Cisco, Merck share losses lead Dow's nearly 75-point drop MarketWatch
Merck & Co., Inc. provides healthcare solutions worldwide. It operates in Pharmaceutical, Animal Health, Healthcare Services, and Alliances segments. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases; neuromuscular blocking agents; cholesterol modifying medicines; and anti-bacterial and vaginal contraceptive products. It also offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat non-small-cell lung, ovarian and breast, thyroid, cervical, and brain cancers; and prevent diseases caused by human papillomavirus, as well as offers vaccines for measles, mumps, rubella, varicella, shingles, rotavirus gastroenteritis, and pneumococcal diseases. In addition, it provides antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, bovine, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fish. Further, it offers companion animal products, such as ointments; diabetes mellitus treatment and anthelmintic products; products to treat fleas and ticks in dogs and cats; horse fertility management products; dog, cat, and horse vaccines; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Intec Pharma Ltd.; Nerviano Medical Sciences; Healthy Interactions, Inc.; Oncologie, Inc.; Themis Bioscience; I-MAB Biopharma Co., Ltd.; 4D pharma plc; Promega Corporation; Seattle Genetics, Inc.; and Astellas Pharma, Inc. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, distributors, veterinarians, animal producers, and managed health care providers. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Nally MichaelEVP, Chief Marketing OfficerOct 30Option Exercise0.002,28706,196Nov 01 05:07 PM
MIZELL STEVENEVP, Chief HR OfficerOct 30Option Exercise0.004,57404,574Nov 01 05:07 PM
Clyburn FrankEVP, Chief Commercial OfficerOct 30Option Exercise0.002,287073,032Nov 01 05:06 PM
Scholefield James HEVP,Chief Info&Digital OfficerOct 30Option Exercise0.0011,436011,436Nov 01 05:04 PM
DeLuca Richard R.EVP&Pres, Merck Animal HeallthAug 09Option Exercise0.006,427077,951Aug 12 05:13 PM
DeLuca Richard R.EVP&Pres, Merck Animal HeallthAug 09Sale85.096,427546,85071,524Aug 12 05:13 PM
DeLuca Richard R.EVP&Pres, Merck Animal HeallthAug 08Option Exercise0.0031,6990103,223Aug 12 05:13 PM
DeLuca Richard R.EVP&Pres, Merck Animal HeallthAug 08Sale85.0131,6992,694,78971,524Aug 12 05:13 PM
Davis Robert MEVP, Global Svcs & CFOJun 25Option Exercise0.00216,7180354,378Jun 27 05:05 PM
Davis Robert MEVP, Global Svcs & CFOJun 25Sale85.43216,71818,514,032137,660Jun 27 05:05 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 10Option Exercise0.003,292022,412May 13 05:06 PM
Clyburn FrankEVP, Chief Commercial OfficerMay 10Option Exercise0.004,389071,993May 13 05:05 PM
Fleming MichaelSVP Chief Ethics & Com OfficerMay 10Option Exercise0.001,50903,317May 13 05:05 PM
Nally MichaelEVP, Chief Marketing OfficerMay 10Option Exercise0.001,81104,376May 13 05:06 PM
Clyburn FrankEVP, Chief Commercial OfficerMay 07Option Exercise39.2925,000982,25092,604May 09 06:11 PM
Clyburn FrankEVP, Chief Commercial OfficerMay 07Sale77.7325,0001,943,18367,604May 09 06:11 PM
Zachary JenniferEVP, General CounselMay 04Option Exercise0.005,77205,772May 07 07:42 PM
Nally MichaelEVP, Chief Marketing OfficerMay 04Option Exercise0.001,29802,935May 07 07:40 PM
Clyburn FrankEVP, Chief Commercial OfficerMay 04Option Exercise0.001,904068,542May 07 07:37 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 04Option Exercise0.001,212019,717May 07 08:32 PM
Fleming MichaelSVP Chief Ethics & Com OfficerMay 04Option Exercise0.0069202,046May 07 08:32 PM
DeLuca Richard R.EVP&Pres, Merck Animal HeallthMay 03Option Exercise39.2935,0001,375,150106,064May 07 08:33 PM
DeLuca Richard R.EVP&Pres, Merck Animal HeallthMay 03Sale80.0035,0002,800,00071,064May 07 08:33 PM
Merck & Co., Inc.10% OwnerApr 08Buy16.004,121,68365,946,92812,955,016Apr 09 06:27 PM
Davis Robert MEVP, Global Svcs & CFOMar 25Option Exercise58.22192,57211,211,542330,232Mar 27 05:45 PM
Davis Robert MEVP, Global Svcs & CFOMar 25Sale82.38192,57215,863,119137,660Mar 27 05:45 PM
FRAZIER KENNETH CChairman, President & CEOMar 20Option Exercise39.29192,7367,572,597990,451Mar 20 06:49 PM
FRAZIER KENNETH CChairman, President & CEOMar 20Sale82.05192,73615,813,372797,715Mar 20 06:49 PM
FRAZIER KENNETH CChairman, President & CEOMar 13Option Exercise39.2918,725735,705816,440Mar 14 06:38 PM
FRAZIER KENNETH CChairman, President & CEOMar 13Sale82.0018,7251,535,454797,715Mar 14 06:38 PM
FRAZIER KENNETH CChairman, President & CEOMar 05Option Exercise39.296,961273,498804,676Mar 06 06:13 PM
FRAZIER KENNETH CChairman, President & CEOMar 05Sale82.006,961570,809797,715Mar 06 06:13 PM
FRAZIER KENNETH CChairman, President & CEOMar 04Option Exercise39.2913,144516,428810,859Mar 06 06:13 PM
FRAZIER KENNETH CChairman, President & CEOMar 04Sale82.0113,1441,077,875797,715Mar 06 06:13 PM
FRAZIER KENNETH CChairman, President & CEOFeb 22Option Exercise39.2953,9612,120,128745,911Feb 22 05:16 PM
FRAZIER KENNETH CChairman, President & CEOFeb 22Sale80.0253,9614,318,089691,950Feb 22 05:16 PM
FRAZIER KENNETH CChairman, President & CEOFeb 21Option Exercise39.2941,9921,649,866733,942Feb 22 05:16 PM
FRAZIER KENNETH CChairman, President & CEOFeb 21Sale80.0041,9923,359,452691,950Feb 22 05:16 PM
FRAZIER KENNETH CChairman, President & CEOFeb 19Option Exercise39.2942,7001,677,683734,650Feb 19 05:35 PM
FRAZIER KENNETH CChairman, President & CEOFeb 19Sale80.0242,7003,416,944691,950Feb 19 05:35 PM
FRAZIER KENNETH CChairman, President & CEOFeb 15Option Exercise39.2992,9133,650,552784,863Feb 19 05:35 PM
FRAZIER KENNETH CChairman, President & CEOFeb 15Sale80.0392,9137,436,162691,950Feb 19 05:35 PM
Karachun Rita ASr. VP Fince-Global ControllerFeb 14Option Exercise59.1664,6623,825,55180,837Feb 14 06:02 PM
Karachun Rita ASr. VP Fince-Global ControllerFeb 14Sale78.9664,6625,105,95116,175Feb 14 06:02 PM
WEEKS WENDELL PDirectorFeb 13Option Exercise24.305,000121,5005,100Feb 14 06:02 PM
WEEKS WENDELL PDirectorFeb 13Sale78.715,000393,548100Feb 14 06:02 PM
Chattopadhyay SanatExe V-P & Pres. MMDFeb 12Option Exercise38.1873,7272,815,241125,194Feb 14 06:02 PM
Chattopadhyay SanatExe V-P & Pres. MMDFeb 12Sale78.6273,7275,796,30651,467Feb 14 06:02 PM
BRUN LESLIE ADirectorFeb 08Option Exercise24.305,000121,5005,000Feb 11 05:33 PM
BRUN LESLIE ADirectorFeb 08Sale77.223,052235,6811,948Feb 11 05:33 PM
FRAZIER KENNETH CChairman, President & CEOFeb 05Option Exercise39.29231,5669,098,228923,516Feb 06 05:30 PM
FRAZIER KENNETH CChairman, President & CEOFeb 05Sale78.08231,56618,079,654691,950Feb 06 05:30 PM